Evidence map›Paper›PMID 25265393›Full record

ArticlePloS one2014

Comparison of antibodies hydrolyzing myelin basic protein from the cerebrospinal fluid and serum of patients with multiple sclerosis.

Visilii B Doronin, Taisiya A Parkhomenko, Massimiliano Castellazzi, Marina Padroni, Michela Pastore, Valentina N Buneva, Enrico Granieri, Georgy A Nevinsky

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Visilii B DoroninNovosibirsk Medical University, Ministry of Public Health of Russian Federation, Novosibirsk, Russia.
Taisiya A ParkhomenkoInstitute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Division, Novosibirsk, Russia.
Massimiliano CastellazziMultiple Sclerosis Center, Department of Neurology, Ferrara University, Ferrara, Italy.
Marina PadroniMultiple Sclerosis Center, Department of Neurology, Ferrara University, Ferrara, Italy.
Michela PastoreMultiple Sclerosis Center, Department of Neurology, Ferrara University, Ferrara, Italy.
Valentina N BunevaInstitute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Division, Novosibirsk, Russia; Novosibirsk State University, Novosibirsk, Russia.
Enrico GranieriMultiple Sclerosis Center, Department of Neurology, Ferrara University, Ferrara, Italy.
Georgy A NevinskyInstitute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Division, Novosibirsk, Russia; Novosibirsk State University, Novosibirsk, Russia.
University of Ferrara · ITInstitute of Chemical Biology and Fundamental Medicine · RUNovosibirsk State Medical University · RUNovosibirsk State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was found that antibodies (Abs) against myelin basic protein (MBP) are the major components of the antibody response in multiple sclerosis (MS) patients. We have recently shown that IgGs from sera of MS patients are active in the hydrolysis of MBP. However, in literature there are no available data concerning possible MBP-hydrolyzing Abs in cerebrospinal fluid (CSF) of MS patients. We have shown that the average content of IgGs in their sera is about 195-fold higher than that in their CSF. Here we have compared, for the first time, the average content of lambda- and kappa-IgGs as well as IgGs of four different subclasses (IgG1-IgG4) in CSF and sera of MS patients. The average relative content of lambda-IgGs and kappa -IgGs in the case of CSFs (8.0 and 92.0%) and sera (12.3 and 87.7%) are comparable, while IgG1, IgG2, IgG3, and IgG4: CSF - 40.4, 49.0, 8.2, and 2.5% of total IgGs, respectively and the sera - 53.6, 36.0, 5.6, and 4.8%, decreased in different order. Electrophoretically and immunologically homogeneous IgGs were obtained by sequential affinity chromatography of the CSF proteins on protein G-Sepharose and FPLC gel filtration. We present first evidence showing that IgGs from CSF efficiently hydrolyze MBP and that their average specific catalytic activity is unpredictably ∼54-fold higher than that of Abs from sera of the same MS patients. Some possible reasons of these findings are discussed. We suggest that anti-MBP abzymes of CSF may promote important neuropathologic mechanisms in this chronic inflammatory disorder and in MS pathogenesis development.

Indexed as

AdultAutoantibodiesFemaleHumansHydrolysisMaleMiddle AgedMultiple SclerosisMyelin Basic ProteinYoung AdultAutoantibodiesMyelin Basic Protein

Identifiers

PMID25265393
PMCPMC4180057
OpenAlexW2000338201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.